Denali Therapeutics Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 1.27 million compared to USD 3.56 million a year ago. Net loss was USD 99.35 million compared to USD 103.3 million a year ago. Basic loss per share from continuing operations was USD 0.72 compared to USD 0.84 a year ago.
For the nine months, revenue was USD 330.53 million compared to USD 98.18 million a year ago. Net loss was USD 25.75 million compared to USD 227.31 million a year ago. Basic loss per share from continuing operations was USD 0.19 compared to USD 1.85 a year ago.